Mark Hayes

1.3k total citations
21 papers, 983 citations indexed

About

Mark Hayes is a scholar working on Molecular Biology, Biomaterials and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Hayes has authored 21 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Biomaterials and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Hayes's work include Nanoparticle-Based Drug Delivery (11 papers), RNA Interference and Gene Delivery (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Mark Hayes is often cited by papers focused on Nanoparticle-Based Drug Delivery (11 papers), RNA Interference and Gene Delivery (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Mark Hayes collaborates with scholars based in United States and China. Mark Hayes's co-authors include Daryl C. Drummond, Dmitri B. Kirpotin, Charles O. Noble, John W. Park, James D. Marks, Keelung Hong, Christopher C. Benz, Zexiong Guo, Yu Zhou and Hao Zou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Journal of Molecular Biology.

In The Last Decade

Mark Hayes

21 papers receiving 960 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Hayes United States 14 558 503 241 185 167 21 983
Jonathan D. Ashley United States 13 721 1.3× 551 1.1× 273 1.1× 117 0.6× 157 0.9× 16 1.3k
Michael Teifel Germany 15 602 1.1× 483 1.0× 300 1.2× 97 0.5× 222 1.3× 34 1.1k
Elaine H. Moase Canada 14 807 1.4× 640 1.3× 273 1.1× 230 1.2× 149 0.9× 18 1.2k
Olivier Meyer United States 10 882 1.6× 798 1.6× 379 1.6× 159 0.9× 182 1.1× 17 1.6k
Vladimir G. Omelyanenko United States 13 709 1.3× 466 0.9× 199 0.8× 133 0.7× 120 0.7× 21 1.2k
Sebastian C.J. Steiniger United States 11 460 0.8× 258 0.5× 173 0.7× 73 0.4× 152 0.9× 12 804
Sara Zalba Spain 17 604 1.1× 520 1.0× 370 1.5× 98 0.5× 204 1.2× 29 1.2k
Charles Engbers United States 9 471 0.8× 521 1.0× 204 0.8× 97 0.5× 124 0.7× 12 912
Atsuhide Mori United States 8 526 0.9× 485 1.0× 185 0.8× 103 0.6× 86 0.5× 10 877
Bing-Mae Chen Taiwan 16 516 0.9× 440 0.9× 252 1.0× 247 1.3× 156 0.9× 20 1.1k

Countries citing papers authored by Mark Hayes

Since Specialization
Citations

This map shows the geographic impact of Mark Hayes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Hayes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Hayes more than expected).

Fields of papers citing papers by Mark Hayes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Hayes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Hayes. The network helps show where Mark Hayes may publish in the future.

Co-authorship network of co-authors of Mark Hayes

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Hayes. A scholar is included among the top collaborators of Mark Hayes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Hayes. Mark Hayes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kirpotin, Dmitri B., et al.. (2022). Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan. Journal of Pharmaceutical Sciences. 112(2). 416–434. 10 indexed citations
2.
Ho, Pui Yan, Zhen Zhang, Mark Hayes, et al.. (2021). Peptide nucleic acid–dependent artifact can lead to false-positive triplex gene editing signals. Proceedings of the National Academy of Sciences. 118(45). 7 indexed citations
3.
Tang, Jie, Wenmin Yuan, Yayuan Liu, et al.. (2018). Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome. European Journal of Pharmaceutics and Biopharmaceutics. 134. 107–116. 33 indexed citations
4.
Yuan, Wenmin, Rui Kuai, Zhipeng Dai, et al.. (2016). Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes. The AAPS Journal. 19(1). 150–160. 34 indexed citations
5.
Kirpotin, Dmitri B., Suresh K. Tipparaju, Zhaohua Huang, et al.. (2016). Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome. Cancer Research. 76(14_Supplement). 3912–3912. 4 indexed citations
6.
7.
8.
Noble, Charles O., Michal T. Krauze, Daryl C. Drummond, et al.. (2014). Pharmacokinetics, Tumor Accumulation and Antitumor Activity of Nanoliposomal Irinotecan Following Systemic Treatment of Intracranial Tumors. Nanomedicine. 9(14). 2099–2108. 20 indexed citations
9.
Kirpotin, Dmitri B., Charles O. Noble, Mark Hayes, et al.. (2011). Building and Characterizing Antibody-Targeted Lipidic Nanotherapeutics. Methods in enzymology on CD-ROM/Methods in enzymology. 502. 139–166. 18 indexed citations
10.
Drummond, Daryl C., Charles O. Noble, Zexiong Guo, et al.. (2009). Development of a highly stable and targetable nanoliposomal formulation of topotecan. Journal of Controlled Release. 141(1). 13–21. 87 indexed citations
11.
Noble, Charles O., Zexiong Guo, Mark Hayes, et al.. (2009). Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemotherapy and Pharmacology. 64(4). 741–751. 57 indexed citations
12.
Drummond, Daryl C., Charles O. Noble, Zexiong Guo, et al.. (2008). Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine. Journal of Pharmacology and Experimental Therapeutics. 328(1). 321–330. 41 indexed citations
13.
Drummond, Daryl C., Charles O. Noble, Mark Hayes, John W. Park, & Dmitri B. Kirpotin. (2008). Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of Pharmaceutical Sciences. 97(11). 4696–4740. 237 indexed citations
14.
Zhou, Yu, Daryl C. Drummond, Hao Zou, et al.. (2007). Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells. Journal of Molecular Biology. 371(4). 934–947. 125 indexed citations
15.
Drummond, Daryl C., Fraser Conrad, Mark Hayes, et al.. (2007). Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Molecular Cancer Therapeutics. 6(10). 2737–2746. 67 indexed citations
16.
Hayes, Mark, Daryl C. Drummond, Keelung Hong, et al.. (2006). Increased Target Specificity of Anti-HER2 Genospheres by Modification of Surface Charge and Degree of PEGylation. Molecular Pharmaceutics. 3(6). 726–736. 29 indexed citations
17.
Hayes, Mark, et al.. (2006). Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1758(4). 429–442. 28 indexed citations
18.
Hayes, Mark, Daryl C. Drummond, Dmitri B. Kirpotin, et al.. (2005). Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Therapy. 13(7). 646–651. 61 indexed citations
19.
Drummond, Daryl C., Charles O. Noble, Zexiong Guo, et al.. (2005). Development of a highly stable liposomal irinotecan with low toxicity and potent antitumor efficacy. 65. 330–330. 1 indexed citations
20.
Noble, Charles O., Dmitri B. Kirpotin, Mark Hayes, et al.. (2004). Development of ligand-targeted liposomes for cancer therapy. Expert Opinion on Therapeutic Targets. 8(4). 335–353. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan D. Ashley Breakdown of academic impact, for papers by Michael Teifel Breakdown of academic impact, for papers by Elaine H. Moase Breakdown of academic impact, for papers by Olivier Meyer Breakdown of academic impact, for papers by Vladimir G. Omelyanenko Breakdown of academic impact, for papers by Sebastian C.J. Steiniger Breakdown of academic impact, for papers by Sara Zalba Breakdown of academic impact, for papers by Charles Engbers Breakdown of academic impact, for papers by Atsuhide Mori Breakdown of academic impact, for papers by Bing-Mae Chen
Rankless by CCL
2026